References

References

Berlana D, Llop JM, Manresa F et al. (2011) Outpatient treatment of Pseudomonas aeruginosa bronchial colonization with long-term inhaled colistin, tobramycin, or both in adults without cystic fibrosis. Pharmacotherapy 31: 146−57

British Thoracic Society (2010) Guideline for non-CF bronchiectasis.

Dhar R, Anwar GA, Bourke SC et al. (2010) Efficacy of nebulised colomycin in patients with non-cystic fibrosis bronchiectasis colonised with Pseudomonas aeruginosa. Thorax 65: 553

Forest Laboratories UK (2012) Colomycin injection summary of product characteristics. [online; accessed 13 November 2013]

Forest Laboratories UK (2013) Colobreathe summary of product characteristics. [online; accessed 13 November 2013]

Haymarket Medical Media (2013) MIMS. [online; accessed 13 November 2013]

Health and Social Care Information Centre (2013) Prescription cost analysis for England 2012. [online; accessed 13 November 2013]

National Institute for Health and Care Excellence (2013) Colistimethate sodium and tobramycin dry powders for inhalation for treating pseudomonas lung infection in cystic fibrosis. NICE technology appraisal guidance 276

ISRCTN Register (2011) Inhaled Promixin® in the treatment of non-cystic fibrosis bronchiectasis. [online; accessed 13 November 2013]

Profile Pharma (2011) Promixin 1 million International Units (IU) powder for nebuliser solution summary of product characteristics. [online; accessed 13 November 2013]

Steinfort DP, Steinfort C (2007) Effect of long-term nebulized colistin on lung function and quality of life in patients with chronic bronchial sepsis. Internal Medicine Journal 37: 495−8

White L, Mirrani G, Grover M et al. (2012) Outcomes of pseudomonas eradication therapy in patients with non-cystic fibrosis bronchiectasis. Respiratory Medicine 106: 356−60